News
A small protein involved in neurodegeneration leading to Parkinson's disease also drives a type of skin cancer known as ...
A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 ... which cleared phase 1, but was side-lined for strategic reasons, and also abandoned an alpha-syn gene therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results